Ardelyx (ARDX) shares plummeted 5.21% in pre-market trading on Friday following the release of the company's first-quarter financial results.
The biopharmaceutical company reported a net loss of $0.15 per diluted share for Q1, which missed analyst expectations of a $0.14 loss. Despite revenue for the quarter coming in at $94.5 million and exceeding consensus estimates, investors appeared to focus on the earnings miss.
The market reaction suggests traders were digesting the mixed quarterly performance, with the earnings shortfall outweighing the positive revenue surprise in pre-market trading.